miR-142-3p as Potential Biomarker of Synaptopathy in MS

Clinical Trial ID NCT03999788

Rank	Title	Journal	Year	PubWeight™‹?›
1	Risk alleles for multiple sclerosis identified by a genomewide study.	N Engl J Med	2007	17.06
2	Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis.	J Neurosci	2009	1.59
3	Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis.	Neurology	2007	0.97
4	Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis.	Eur J Neurol	2009	0.93
5	Biomarkers in multiple sclerosis.	Clin Immunol	2015	0.88
6	Biomarkers of therapeutic response in multiple sclerosis: current status.	Mol Diagn Ther	2014	0.87
7	Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.	Nat Rev Neurol	2015	0.85
8	miRNA in multiple sclerosis: search for novel biomarkers.	Mult Scler	2015	0.82
9	MicroRNAs in the CSF: macro-advance in MS?	Neurology	2012	0.78
10	Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.	J Neuroinflammation	2016	0.77
11	Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and Severity.	Int J Mol Sci	2015	0.76
12	miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands.	Mult Scler	2017	0.75
13	Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.	Neurol Neuroimmunol Neuroinflamm	2016	0.75
14	miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.	J Neurosci	2017	0.75